| Today’s Big NewsAug 14, 2023 |
| By James Waldron The FDA has put an early-phase trial of 2seventy bio’s CD33-targeted CAR-T cell therapy on hold in the wake of a patient death. |
|
|
|
| Philadelphia, PA |  |
|
|
By Annalee Armstrong Incyte has ended a five-year collaboration with Syros Pharmaceuticals after seven targets were identified for myeloproliferative neoplasms and none taken back to the lab for further development. |
By Nick Paul Taylor BioXcel Therapeutics is cutting deep to cope with the collapse of its cash runway. With BioXcel unlikely to meet the requirements for an anticipated cash infusion, the biotech is laying off almost 60% of its staff and narrowing its focus to keep going through the middle of next year. |
By James Waldron The walls seemed to be closing in on Fresh Tracks Therapeutics when, in March, the company began searching for a potential buyer to overcome its limited resources. But only now has the biotech revealed that its R&D work has been placed on pause to hold onto more cash. |
By Nick Paul Taylor The FDA is making Valneva wait. Two weeks from the original deadline, the agency has pushed back its decision on whether to approve Valneva’s chikungunya virus vaccine candidate by three months. |
By Gabrielle Masson Gracell Biotechnologies is shaving down its CAR-T pipeline, throwing several programs out the window in an effort to speed its most advanced programs to the finish line. |
By Helen Floersh From CRISPR and artificial intelligence to an old, once-rejected drug, the arsenal of potential weapons against antibiotic resistance is, thankfully, growing at last. The latest: a synthetic antibiotic that holds bacteria back by blocking the development of their vital outer membrane. |
By Max Bayer Bristol Myers Squibb has laid off more than 100 employees amid a reconfiguration of expenses that follows disappointing earnings results. |
By Andrea Park Though rebuked by shareholders in a vote earlier this year that kept its executives potentially liable for any legal issues related to its recent recall-related troubles, Philips has gotten a major confidence boost from a new investor. |
By Fraiser Kansteiner As layoffs continue to roil the biotech industry, bigger drugmakers and manufacturers like Bristol Myers Squibb and Emergent BioSolutions haven’t been immune. Now, Thermo Fisher Scientific is among the latest to plot hundreds of job cuts. |
By Ben Adams Novartis has been consistently pushing the boundaries in digital pharma for years. However, the company has now encountered the intricate challenges associated with navigating regulatory guidelines. This has become evident as the Big Pharma has been hit with the U.K.'s most most serious drug marketing breach. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research. |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Secure your spot today and save $400 on registration. Savings end August 21st! 
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
